Nyxoah appointed Liam Kelly as CEO, effective October 1. Kelly previously led Teleflex as Chairman, President and CEO until January 2026. He succeeds Olivier Taelman. The change comes as Nyxoah focuses on US commercialization of its Genio hypoglossal neurostimulation system, which received FDA approval in August 2025.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
